cerca CERCA
Giovedì 29 Settembre 2022
Aggiornato: 00:06
Temi caldi

protein based COVID

comunicato stampa

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

GAITHERSBURG, Md., April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that its partner, Takeda,  received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for its Nuvaxovid™ Intramuscular Injection (Nuvaxovid), Novavax' novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization ...

comunicato stampa

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

GAITHERSBURG, Md. and PUNE, India, March 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' protein-based COVID-19 vaccine for adolescents aged ≥12 to <18...

comunicato stampa

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

GAITHERSBURG, Md. and PUNE, India, Dec. 28, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine w...

comunicato stampa

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vacc...

comunicato stampa

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia

GAITHERSBURG, Md. and PUNE, India, Nov. 1, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan (Badan POM), has granted emergency use authorization...

ora in
Prima pagina
articoli
in Evidenza